Drug Therapy

Sharon J. Longshore, RPH, MD
Department of Dermatology, The Cleveland Clinic

Kimberly Hollandsworth, MD
University Hospital Dermatology Associates, Inc., Dermatopathology & General Dermatology, University Hospitals’ Bolwell Health Center, Cleveland

Address: Sharon J. Longshore, RPH, MD, Department of Dermatology, The Cleveland Clinic, A61, 9500 Euclid Avenue, Cleveland, OH 44195

Sharon J. Longshore, RPH, MD
Department of Dermatology, The Cleveland Clinic

Kimberly Hollandsworth, MD
University Hospital Dermatology Associates, Inc., Dermatopathology & General Dermatology, University Hospitals’ Bolwell Health Center, Cleveland

Address: Sharon J. Longshore, RPH, MD, Department of Dermatology, The Cleveland Clinic, A61, 9500 Euclid Avenue, Cleveland, OH 44195

Sharon J. Longshore, RPH, MD
Department of Dermatology, The Cleveland Clinic

Kimberly Hollandsworth, MD
University Hospital Dermatology Associates, Inc., Dermatopathology & General Dermatology, University Hospitals’ Bolwell Health Center, Cleveland

Address: Sharon J. Longshore, RPH, MD, Department of Dermatology, The Cleveland Clinic, A61, 9500 Euclid Avenue, Cleveland, OH 44195

Gustavo A. Cardenas, MD
Section of Preventive Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic

José M. Cabral, MD
Department of Endocrinology, Cleveland Clinic Florida

Camilo A. Leslie, MD, MBA
Department of Endocrinology, Cleveland Clinic Florida; Associate Professor of Medicine (affiliate), University of South Florida College of Medicine

Address: Camilo A. Leslie, MD, Department of Endocrinology, Cleveland Clinic Florida, 2950 Cleveland Clinic Florida Boulevard, Weston, FL 33331; email: [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gustavo A. Cardenas, MD
Section of Preventive Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic

José M. Cabral, MD
Department of Endocrinology, Cleveland Clinic Florida

Camilo A. Leslie, MD, MBA
Department of Endocrinology, Cleveland Clinic Florida; Associate Professor of Medicine (affiliate), University of South Florida College of Medicine

Address: Camilo A. Leslie, MD, Department of Endocrinology, Cleveland Clinic Florida, 2950 Cleveland Clinic Florida Boulevard, Weston, FL 33331; email: [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gustavo A. Cardenas, MD
Section of Preventive Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic

José M. Cabral, MD
Department of Endocrinology, Cleveland Clinic Florida

Camilo A. Leslie, MD, MBA
Department of Endocrinology, Cleveland Clinic Florida; Associate Professor of Medicine (affiliate), University of South Florida College of Medicine

Address: Camilo A. Leslie, MD, Department of Endocrinology, Cleveland Clinic Florida, 2950 Cleveland Clinic Florida Boulevard, Weston, FL 33331; email: [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

Michael Miller, MD
Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, Baltimore

Address: Michael Miller, MD, Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, 22 South Greene St., Room 53B06, Baltimore, MD 21201; e-mail: [email protected]

The author has indicated that he has received grant or research support from the Merck, Pfizer, Kos Pharmaceuticals, and AstraZeneca corporations.

Michael Miller, MD
Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, Baltimore

Address: Michael Miller, MD, Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, 22 South Greene St., Room 53B06, Baltimore, MD 21201; e-mail: [email protected]

The author has indicated that he has received grant or research support from the Merck, Pfizer, Kos Pharmaceuticals, and AstraZeneca corporations.

Michael Miller, MD
Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, Baltimore

Address: Michael Miller, MD, Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, 22 South Greene St., Room 53B06, Baltimore, MD 21201; e-mail: [email protected]

The author has indicated that he has received grant or research support from the Merck, Pfizer, Kos Pharmaceuticals, and AstraZeneca corporations.

Alice I. Kim, MD
Department of Infectious Disease, The Cleveland Clinic

Karim A. Adal, MD
Department of Infectious Disease, The Cleveland Clinic

Steven K. Schmitt, MD
Department of Infectious Disease, The Cleveland Clinic

Address: Steven K. Schmitt, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Alice I. Kim, MD
Department of Infectious Disease, The Cleveland Clinic

Karim A. Adal, MD
Department of Infectious Disease, The Cleveland Clinic

Steven K. Schmitt, MD
Department of Infectious Disease, The Cleveland Clinic

Address: Steven K. Schmitt, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Alice I. Kim, MD
Department of Infectious Disease, The Cleveland Clinic

Karim A. Adal, MD
Department of Infectious Disease, The Cleveland Clinic

Steven K. Schmitt, MD
Department of Infectious Disease, The Cleveland Clinic

Address: Steven K. Schmitt, MD, Department of Infectious Disease, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center; Director, Cardiology Fellowship Training Program; Co-Director, UCLA Preventive Cardiology Program; Associate Professor of Medicine, UCLA Division of Cardiology, Los Angeles

Address: Gregg C. Fonarow, MD, Ahmanson-University of California Los Angeles Cardiomyopathy Center, UCLA Division of Cardiology, 47-123 CHS, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1679; e-mail: [email protected]

The author has indicated that he has received grant or research support from the Bristol-Myers Squibb, Merck, Merck-Schering Plough, and Pfizer corporations, and that he serves as a consultant and is on the speakers’ bureaus of the same corporations.

Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center; Director, Cardiology Fellowship Training Program; Co-Director, UCLA Preventive Cardiology Program; Associate Professor of Medicine, UCLA Division of Cardiology, Los Angeles

Address: Gregg C. Fonarow, MD, Ahmanson-University of California Los Angeles Cardiomyopathy Center, UCLA Division of Cardiology, 47-123 CHS, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1679; e-mail: [email protected]

The author has indicated that he has received grant or research support from the Bristol-Myers Squibb, Merck, Merck-Schering Plough, and Pfizer corporations, and that he serves as a consultant and is on the speakers’ bureaus of the same corporations.

Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center; Director, Cardiology Fellowship Training Program; Co-Director, UCLA Preventive Cardiology Program; Associate Professor of Medicine, UCLA Division of Cardiology, Los Angeles

Address: Gregg C. Fonarow, MD, Ahmanson-University of California Los Angeles Cardiomyopathy Center, UCLA Division of Cardiology, 47-123 CHS, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1679; e-mail: [email protected]

The author has indicated that he has received grant or research support from the Bristol-Myers Squibb, Merck, Merck-Schering Plough, and Pfizer corporations, and that he serves as a consultant and is on the speakers’ bureaus of the same corporations.